Author: Jim Lay

Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025

Read More
Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 29, 2025

Read More
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 29, 2025

Read More
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

April 30, 2025

Read More
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

April 16, 2025

Read More